Cargando…
The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up
Autores principales: | Ujjani, Chaitra S., Poh, Christina, Tu, Brian, Lee, Sydney, Selke, Stacy, Zhu, Haiying, Shadman, Mazyar, Lynch, Ryan C., Huang, Meei-Li W, Gopal, Ajay K., Warren, Edus H., Till, Brian G., Smith, Stephen D, Sperling, Amy, Hill, Joshua A., Stevenson, Philip, Nielsen, Leslie, Gooley, Ted A., Greninger, Alexander L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665301/ http://dx.doi.org/10.1182/blood-2022-170154 |
Ejemplares similares
-
Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021) -
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient
por: Hill, Joshua A., et al.
Publicado: (2021) -
Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
por: Graf, Solomon A., et al.
Publicado: (2021) -
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022) -
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)